GB Sciences, Inc. (GBLX)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
GB Sciences, Inc. (GBLX) with AI Score 49/100 (Weak). GB Sciences, Inc. is a biotechnology company focused on the research and development of plant-based medicines. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 17, 2026GB Sciences, Inc. (GBLX) Healthcare & Pipeline Overview
GB Sciences, Inc., operating in the biotechnology sector, researches and develops plant-based medicines, including cannabinoid-inspired therapies, targeting conditions like Parkinson's disease and neuropathic pain. With pre-clinical programs and a focus on complex therapeutic mixtures, the company aims to serve the prescription drug market in North America and Europe.
Investment Thesis
GB Sciences, Inc. presents a high-risk, high-reward investment profile characteristic of early-stage biotechnology firms. The company's focus on plant-based medicines, particularly cannabinoid-inspired therapies, aligns with growing market interest in alternative treatments. However, with a market capitalization of $0.00B and negative profitability (P/E of -0.28 and a profit margin of -299.6%), the company's financial stability is a significant concern. The company's gross margin is 100.0%. The success of GB Sciences hinges on advancing its pre-clinical programs to clinical trials and ultimately securing regulatory approvals. The high beta of 9.86 indicates extreme volatility. Investors should carefully consider the risks associated with OTC-traded companies and the uncertainty inherent in pharmaceutical development.
Based on FMP financials and quantitative analysis
Key Highlights
- Market Cap of $0.00B reflects the company's small size and early stage of development.
- P/E Ratio of -0.28 indicates the company is not currently profitable.
- Profit Margin of -299.6% demonstrates significant losses relative to revenue.
- Gross Margin of 100.0% suggests high potential profitability if research and development costs can be managed effectively.
- Beta of 9.86 indicates the stock is significantly more volatile than the market average.
Competitors & Peers
Strengths
- Focus on plant-based medicines.
- Intellectual property portfolio.
- Pre-clinical programs targeting unmet medical needs.
- Expertise in cannabinoid-inspired therapies.
Weaknesses
- Limited financial resources.
- Small team size.
- Early stage of development.
- Dependence on external funding and partnerships.
Catalysts
- Upcoming: Announcement of results from pre-clinical studies for Parkinson's disease program (timeline: next 6-12 months).
- Upcoming: Initiation of clinical trials for neuropathic pain therapy (timeline: next 12-18 months, contingent on funding).
- Ongoing: Pursuit of strategic partnerships with larger pharmaceutical companies.
- Ongoing: Expansion of intellectual property portfolio through new patent filings.
- Ongoing: Research and development efforts to advance drug candidates through the pipeline.
Risks
- Potential: Failure to secure funding for clinical trials.
- Potential: Negative results from clinical trials.
- Potential: Regulatory delays or rejection of drug candidates.
- Ongoing: Competition from larger biotechnology companies with greater resources.
- Ongoing: Limited financial resources and dependence on external funding.
Growth Opportunities
- Advancement of Parkinson's Disease Program: GB Sciences has a pre-clinical program targeting Parkinson's disease. The Parkinson's disease treatment market is projected to reach $5.6 billion by 2027. Successfully transitioning this program to clinical trials and demonstrating efficacy could unlock significant value for the company. The timeline for this catalyst depends on securing funding and completing pre-clinical studies, potentially leading to clinical trials within the next 2-3 years.
- Development of Neuropathic Pain Therapies: The company is developing plant-based medicines for neuropathic pain, a market estimated at $8.3 billion globally. Achieving positive results in pre-clinical studies and advancing to clinical trials could position GB Sciences as a player in this large and growing market. This growth opportunity is contingent on successful pre-clinical data, which could lead to clinical trial initiation within 2-3 years.
- Expansion into Cardiovascular Therapeutics: GB Sciences has a cardiovascular therapeutic program in the pre-clinical stage. The global cardiovascular disease market is substantial, offering significant potential for new therapies. Progressing this program through pre-clinical and clinical stages could diversify the company's pipeline and create new revenue streams. This is a longer-term opportunity, with potential clinical trials 3-5 years out.
- Commercialization of COVID-Related Cytokine Release Syndrome Treatment: GB Sciences is researching treatments for COVID-related cytokine release syndrome. While the urgency of the COVID-19 pandemic has decreased, there remains a need for effective treatments for complications arising from the virus. Successful development and commercialization of such a treatment could provide a near-term revenue opportunity. This opportunity depends on ongoing research and potential regulatory pathways, possibly yielding results within the next 1-2 years.
- Strategic Partnerships and Licensing Agreements: GB Sciences can pursue strategic partnerships with larger pharmaceutical companies to accelerate the development and commercialization of its drug candidates. Licensing agreements can provide upfront payments, milestone payments, and royalties, generating revenue and validating the company's technology. The timing and success of such partnerships are uncertain but represent a potential growth driver in the near to medium term.
Opportunities
- Growing market for plant-based medicines.
- Strategic partnerships with larger pharmaceutical companies.
- Advancement of pre-clinical programs to clinical trials.
- Expansion into new therapeutic areas.
Threats
- Regulatory hurdles and approval processes.
- Competition from larger biotechnology companies.
- Uncertainty in clinical trial outcomes.
- Fluctuations in market demand for plant-based therapies.
Competitive Advantages
- Intellectual property portfolio covering various therapeutic areas.
- Expertise in developing cannabinoid-inspired medicines.
- Focus on plant-based therapies, aligning with growing market trends.
- Proprietary formulations and drug delivery systems.
About GBLX
GB Sciences, Inc., founded in 2001 and based in Las Vegas, Nevada, is a biotechnology company dedicated to the research and development of plant-based medicines. Originally incorporated as Growblox Sciences, Inc., the company rebranded in October 2016 to reflect its evolving focus. GB Sciences develops cannabinoid-inspired medicines and complex therapeutic mixtures intended for the prescription drug market. Their research spans a range of conditions, including Parkinson's disease, neuropathic pain, chronic pain, COVID-related cytokine release syndrome, depression/anxiety, and cardiovascular ailments. The company's intellectual property portfolio covers these therapeutic areas, with programs currently in the pre-clinical animal stage. GB Sciences operates in both North America and Europe, seeking to bring innovative, plant-based solutions to address unmet medical needs. Their strategy involves rigorous scientific investigation and the development of proprietary formulations to create effective and safe therapies. With a small team of 2 employees, the company outsources many functions. GB Sciences is positioned to capitalize on the growing acceptance of plant-based medicines and the increasing demand for novel therapeutic options.
What They Do
- Researches and develops plant-based medicines.
- Focuses on cannabinoid-inspired therapies.
- Targets conditions like Parkinson's disease, neuropathic pain, and chronic pain.
- Develops complex therapeutic mixtures for the prescription drug market.
- Conducts pre-clinical animal studies to evaluate drug candidates.
- Seeks to create innovative and effective treatments for unmet medical needs.
- Operates in North America and Europe.
Business Model
- Develops proprietary plant-based medicine formulations.
- Out-licenses or partners with larger pharmaceutical companies for clinical trials and commercialization.
- Generates revenue through licensing fees, milestone payments, and royalties.
Industry Context
GB Sciences operates within the biotechnology industry, a sector characterized by high innovation, intense competition, and significant regulatory hurdles. The market for plant-based medicines is expanding, driven by increasing consumer interest in natural and alternative therapies. However, the industry is also subject to stringent regulations and lengthy approval processes. GB Sciences competes with other biotechnology companies, including ACUS, BIOAF, EHOS, GSTC and HTDS, some of which have greater resources and more advanced clinical programs. Success in this industry requires strong scientific expertise, effective regulatory strategies, and substantial capital investment.
Key Customers
- Pharmaceutical companies seeking novel drug candidates.
- Patients with conditions like Parkinson's disease, neuropathic pain, and chronic pain.
- Healthcare providers prescribing plant-based medicines.
Financials
Chart & Info
GB Sciences, Inc. (GBLX) stock price: Price data unavailable
Latest News
-
Stocks That Hit 52-Week Lows On Thursday
· Nov 14, 2019
-
Stocks That Hit 52-Week Lows On Friday
· Nov 8, 2019
-
Stocks That Hit 52-Week Lows On Tuesday
· Oct 15, 2019
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for GBLX.
Price Targets
Wall Street price target analysis for GBLX.
MoonshotScore
What does this score mean?
The MoonshotScore rates GBLX's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Andrea Small-Howard
Chief Executive Officer
Andrea Small-Howard serves as the Chief Executive Officer of GB Sciences, Inc. Her background includes experience in the pharmaceutical and biotechnology industries. She has a strong understanding of drug development, regulatory affairs, and commercialization strategies. Her expertise is crucial for guiding GB Sciences through its pre-clinical and clinical development programs. She is responsible for overseeing the company's overall strategy and operations, including research and development, business development, and investor relations.
Track Record: Under Andrea Small-Howard's leadership, GB Sciences has focused on advancing its pre-clinical programs and expanding its intellectual property portfolio. She has been instrumental in securing funding and establishing strategic partnerships to support the company's growth. Her leadership is focused on driving innovation and creating value for shareholders through the development of novel plant-based medicines. She is managing 2 employees.
GBLX OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that GB Sciences may not meet the minimum financial or disclosure requirements of the higher tiers (OTCQX and OTCQB). Companies on this tier may have limited financial reporting, making it more difficult for investors to assess their financial health and performance compared to companies listed on major exchanges like the NYSE or NASDAQ. Investing in companies on the OTC Other tier carries a higher degree of risk due to the lack of regulatory oversight and transparency.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure increases information asymmetry.
- Low trading volume and liquidity can lead to price volatility.
- Higher potential for fraud and manipulation compared to listed exchanges.
- OTC Other tier status indicates potential financial or operational challenges.
- Dependence on external funding and partnerships.
- Verify the company's financial statements and SEC filings (if any).
- Research the background and experience of the company's management team.
- Assess the company's intellectual property portfolio and competitive landscape.
- Evaluate the company's funding sources and cash runway.
- Understand the risks associated with investing in OTC-traded companies.
- Consult with a financial advisor before making any investment decisions.
- Confirm the company's good standing with the state of incorporation.
- Focus on research and development of plant-based medicines.
- Intellectual property portfolio covering various therapeutic areas.
- CEO with experience in the pharmaceutical and biotechnology industries.
- Company incorporated in 2001.
GB Sciences, Inc. Stock: Key Questions Answered
What does GB Sciences, Inc. do?
GB Sciences, Inc. is a biotechnology company focused on the research and development of plant-based medicines, particularly cannabinoid-inspired therapies. The company aims to create complex therapeutic mixtures for the prescription drug market, targeting conditions such as Parkinson's disease, neuropathic pain, chronic pain, and COVID-related cytokine release syndrome. Their work is currently in the pre-clinical stage, involving animal studies to assess the safety and efficacy of their drug candidates. The company operates in North America and Europe, seeking to address unmet medical needs through innovative, plant-based solutions.
What do analysts say about GBLX stock?
As of March 17, 2026, there is no readily available analyst coverage or consensus on GB Sciences, Inc. (GBLX) due to its OTC listing and small market capitalization. Investors should conduct their own thorough due diligence and consider the risks associated with investing in OTC-traded companies. Key valuation metrics, such as price-to-earnings ratio and revenue growth, may not be meaningful due to the company's current financial performance. Growth considerations depend on the successful advancement of pre-clinical programs and securing regulatory approvals.
What are the main risks for GBLX?
The main risks for GB Sciences, Inc. include its limited financial resources, dependence on external funding, and the inherent uncertainties of drug development. The company's pre-clinical programs face the risk of failure in clinical trials or regulatory rejection. Competition from larger biotechnology companies with greater resources poses a significant challenge. As an OTC-traded company, GBLX is subject to lower levels of regulatory oversight and greater price volatility. Investors should carefully consider these risks before investing in GBLX.
What are the key factors to evaluate for GBLX?
GB Sciences, Inc. (GBLX) currently holds an AI score of 49/100, indicating low score. Key strength: Focus on plant-based medicines.. Primary risk to monitor: Potential: Failure to secure funding for clinical trials.. This is not financial advice.
How frequently does GBLX data refresh on this page?
GBLX prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven GBLX's recent stock price performance?
Recent price movement in GB Sciences, Inc. (GBLX) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Focus on plant-based medicines.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider GBLX overvalued or undervalued right now?
Determining whether GB Sciences, Inc. (GBLX) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying GBLX?
Before investing in GB Sciences, Inc. (GBLX), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available company information and may be limited due to the company's OTC listing.
- AI analysis pending for GBLX.